Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

nufacturing and marketing FavId or Favrille's other product candidates; delays in the availability of data from Favrille's Phase 3 clinical trial; Favrille's ability to obtain marketing approval for FavId or Favrille's other product candidates and the timing of any such approvals, including whether a clinically meaningful response improvement can serve as the basis for accelerated approval of FavId and whether it will receive expedited review as a result of the Fast Track designation; Favrille's ability to demonstrate that its idiotype protein produced from insect cell lines may stimulate a more effective immune response compared to idiotype protein derived from mammalian cells; Favrille's ability to manufacture sufficient quantities of FavId for use in clinical trials and, if FavId receives marketing approval, for commercialization; risks associated with achieving projected operating metrics and financial performance or the anticipated number of patients using FavId; potential delays in patient enrollment; Favrille's ability to obtain additional financing to support its operations, including the conditions to the Company's ability to access the committed equity financing facility and therefore fund operations through the first half of 2008; and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. In addition, conclusions regarding the safety and efficacy of Favrille's product candidates cannot be made until the results of future clinical trials of longer duration in more patients are known. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.


'/>"/>
SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Dendreon Corporation (Nasdaq: DNDN ) today announced that management ... Healthcare Conference in New York City, NY on May 25, 2011 ... in Rancho Palos Verdes, CA on June 7, 2011 at 2:00 ... live and available for replay from Dendreon,s website, www.dendreon.com . ...
... BRISBANE, Calif., May 19, 2011 InterMune, Inc. (NASDAQ: ... of its 2011 Analyst Day presentations on Thursday, May ... in New York.  Presentations by InterMune,s executive management team ... and a comprehensive update of InterMune,s commercial and scientific ...
... CARY, N.C., May 19, 2011 ... its flexible 100% web-based Life Science Study Management ... successfully used globally by Leading European and USA ... eStudy,s on-line study design, management, communication, data collection ...
Cached Biology Technology:InterMune to Webcast 2011 Analyst Day Presentations 2Leading Ag Biotechnology Companies in Europe and America Save 50-80% of Field Study Management Time with eStudy 2Leading Ag Biotechnology Companies in Europe and America Save 50-80% of Field Study Management Time with eStudy 3
(Date:7/9/2014)... geographic ranges in which animals can be found, concern ... Does an increased range for a host mean new ... says a team of UC Santa Barbara scientists, including ... published in the Journal of Biogeography , Hechinger, ... opposite may happen: Hosts may actually lose their parasites ...
(Date:7/9/2014)... (July 9, 2014) Emerging fungal pathogens pose ... parasitic group, causing population declines of amphibians, bats, ... University of South Florida published in the prestigious ... acquire behavioral or immunological resistance to a deadly ... , "Acquired resistance is important because it ...
(Date:7/9/2014)... injuries have identified an immune marker that predicts ... infection. The study, led by clinician-scientists at Nationwide ... the journal Shock , is part of ... clinical implementation of quick-turnaround immune function tests and ... following critical illness or injury in pediatric patients. ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... stem cells, ability to regenerate damaged tissue could offer ... myopathy and muscular dystrophy, according to researchers from the ... procedure has been successfully used to regrow muscles in ... all tissue-based illnesses in humans such as in the ...
... young, apparently healthy athletes suddenly collapse, it can be due ... have now discovered a genetic modification that leads to cardiac ... can give zebrafish a heart condition. Since the fish have ... could be critical for humans as well. ...
... and Innovation in Global BiometricsGAITHERSBURG, Md., March 4 ... has been named the Biometrics Systems Integrator "Company ... the Corporation,s leadership in developing innovative biometrics solutions ... Sullivan based the award on a rigorous analysis ...
Cached Biology News:Stem cell breakthrough gives new hope to sufferers of muscle-wasting diseases 2Why 'lazy Susan' has a weak heart 2Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2
...
... An entire pressurized perfusion system ... in physiology, biophysics, electrochemistry, or general ... as little as 100 microliters of ... eight solutions in milliseconds from a ...
...
Request Info...
Biology Products: